Business Context and Reporting Period
This Form 8-K was filed by 22nd Century Group, Inc. on August 18, 2021. The report discloses a corporate governance event: the appointment of a new director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The material change reported is the appointment of Anthony Johnson as a Class II director, effective immediately on August 18, 2021, to fill an existing vacancy. Mr. Johnson is independent under NASDAQ rules and will serve on the Scientific, Finance, and Compensation Committees.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of risks and contingencies. Management commentary is limited to a biographical summary of Mr. Johnson's background in gene therapy, biosciences, and oncology, noting his roles at Kodikaz Therapeutic Solutions and Buffalo Biosciences. No unusual items or related party transactions were disclosed.
Investor Verification Checklist
- Verify the independence status of the newly appointed director, Anthony Johnson, under NASDAQ listing rules.
- Confirm the specific compensation package for non-employee directors to ensure alignment with existing board members.
- Review the attached press release (Exhibit 99.1) for additional details on the strategic rationale for this appointment.
- Check subsequent filings for any changes to the composition of the Scientific, Finance, and Compensation Committees.